Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Harvard Business School
Mallinckrodt
Colorcon

Last Updated: May 28, 2022

Investigational Drug Information for LUM001


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug LUM001?

LUM001 is an investigational drug.

There have been 14 clinical trials for LUM001. The most recent clinical trial was a Phase 2 trial, which was initiated on July 9th 2019.

The most common disease conditions in clinical trials are Cholestasis, Syndrome, and Liver Diseases. The leading clinical trial sponsors are Mirum Pharmaceuticals, Inc., Shire, and Lumena Pharmaceuticals, Inc.

There are ten US patents protecting this investigational drug and three hundred and seventy-eight international patents.

Recent Clinical Trials for LUM001
TitleSponsorPhase
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).Mirum Pharmaceuticals, Inc.Phase 2
Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiMirum Pharmaceuticals, Inc.Phase 2
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)Mirum Pharmaceuticals, Inc.Phase 3

See all LUM001 clinical trials

Clinical Trial Summary for LUM001

Top disease conditions for LUM001
Top clinical trial sponsors for LUM001

See all LUM001 clinical trials

US Patents for LUM001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LUM001 See Plans and Pricing Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions SATIOGEN PHARMACEUTICALS, INC. (San Diego, CA) See Plans and Pricing
LUM001 See Plans and Pricing Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases LUMENA PHARMACEUTIALS LLC (Lexington, MA) See Plans and Pricing
LUM001 See Plans and Pricing Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL) See Plans and Pricing
LUM001 See Plans and Pricing Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL) See Plans and Pricing
LUM001 See Plans and Pricing Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LUM001

Drugname Country Document Number Estimated Expiration Related US Patent
LUM001 European Patent Office EP2575821 2030-05-26 See Plans and Pricing
LUM001 European Patent Office EP2995317 2030-05-26 See Plans and Pricing
LUM001 European Patent Office EP3593802 2030-05-26 See Plans and Pricing
LUM001 Spain ES2552657 2030-05-26 See Plans and Pricing
LUM001 World Intellectual Property Organization (WIPO) WO2011150286 2030-05-26 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Harvard Business School
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.